A prospective naturalistic study of antidepressant-induced jitteriness/anxiety syndrome

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 2115-2121

  Harada, Tsuyoto ^a   Inada, Ken ^a   Yamada, Kazuo ^a   Sakamoto, Kaoru ^a   Ishigooka, Jun ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Antidepressants; Selective serotonin reuptake inhibitors; Side effects; Suicide; Tricyclic antidepressive agents

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG INDICATION; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MOOD DISORDER; NATURALISTIC INQUIRY; NERVOUSNESS; PRESCRIPTION; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84910103272     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S70637     Document Type: Article

References (28)

1. King RA, Riddle MA, Chappell PB, et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry. 1991;30(2):179-186.
2. Friedman EH. Tricyclic-induced activation/jitteriness. J Clin Psychopharmacol. 1991;11(6):394-395.
3. Jackson CW, Lydiard RB. Two cases of activation/jitteriness associated with TCAs. J Clin Psychopharmacol. 1990;10(6):439-440.
4. Pohl R, Yeragani VK, Ortiz A, Rainey JM Jr, Gershon S. Response of tricyclic-induced jitteriness to a phenothiazine in two patients. J Clin Psychiatry. 1986;47(8):427.
5. Yeragani VK, Pohl R, Balon R. Tricyclics, akathisia, and jitteriness. J Clin Psychopharmacol. 1988;8(4):295.
6. Yeragani VK, Pohl R, Balon R, Kulkarni A, Keshavan M. Low serum iron levels and tricyclic antidepressant-induced jitteriness. J Clin Psychopharmacol. 1989;9(6):447-448.
7. US Food and Drug Administration. Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). 2003. Available from: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm168828.htm. Accessed October 24, 2014.
8. US Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressants. 2004. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm161696.htm. Accessed October 24, 2014.
9. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry. 2006;163(5):813-821.
10. Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry. 2007;164(7):1029-1034.
11. Tondo L, Lepri B, Baldessarini RJ. Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiatr Scand. 2008;118(2):106-115.
12. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41-47.
13. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339.
14. Rotenberg VS. Functional brain asymmetry as a determinative factor in the treatment of depression: theoretical implications. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1772-1777.
15. Rotenberg VS. Search activity concept: relationship between behavior, health and brain functions. Activitas Nervosa Superior. 2009;51(1):12-44.
16. Takeshima M, Oka T. Association between the so-called "activation syndrome" and bipolar II disorder, a related disorder, and bipolar suggestive features in outpatients with depression. J Affect Disord. 2013;151(1):196-202.
17. Kraus JE, Horrigan JP, Carpenter DJ, Fong R, Barrett PS, Davies JT. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. J Affect Disord. 2010;120(1-3):40-47.
18. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry. 2009;194(6):483-490.
19. Beasley CM Jr, Potvin JH. Fluoxetine: activating and sedating effects. Int Clin Psychopharmacol. 1993;8(4):271-275.
20. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry. 1994;55(9):394-400.
21. Harada T, Sakamoto K, Ishigooka J. Incidence and predictors of activation syndrome induced by antidepressants. Depress Anxiety. 2008;25(12):1014-1019.
22. Akiskal HS, Hantouche EG, Allilaire JF, et al. Validating antidepressant-associated hypomania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II). J Affect Disord. 2003;73(1-2):65-74.
23. Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med. 2007;356(23):2343-2346.
24. Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics. 2010;125(5):876-888.
25. Schneeweiss S, Patrick AR, Solomon DH, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry. 2010;67(5):497-506.
26. Hammad TA. Results of the analysis of suicidality in pediatric trials of newer antidepressants. 2004. Available from: http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1_08_FDA-Hammad.ppt. Accessed September 19, 2014.
27. Yeragani VK, Pohl R, Balon R, Ramesh C, Weinberg P. Imipramine-induced jitteriness and decreased serum iron levels. Neuropsychobiology. 1992;25(1):8-10.
28. Beasley CM Jr, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol. 1992;12(5):328-333.